2024 PDA
VIRUS
CONFERENCE

pda.org/EU/2024Virus

26-27 JUNE 2024
AMSTERDAM, THE NETHERLANDS
EXHIBITION: 26-27 JUNE 2024
WORKSHOP: 28 JUNE 2024

CALL FOR ABSTRACTS

ABSTRACT SUBMISSION DEADLINE:
30 NOVEMBER 2023
WELCOME FROM THE CO-CHAIRS

Dear Colleague,

We would like to invite you to submit a paper or poster abstract for presentation for the 2024 PDA Virus Conference to be held on 26-27 June 2024 in Amsterdam, The Netherlands.

Abstracts must be non-commercial in nature, describing new developments or work that significantly contributes to the body of knowledge relating to virus safety and all related aspects as stated below.

The Scientific Program Planning Committee will review all proposals carefully and consider podium and poster contributions.

We look forward to receiving your topic proposal!

Sincerely,

The Co-Chairs

CALL FOR ABSTRACTS

TOPICS AREAS OF INTEREST WILL INCLUDE BUT ARE NOT LIMITED TO THE FOLLOWING

1. REGULATORY UPDATES
   - International Perspectives
   - Updates on EP/USP/JP Chapters
   - Update on ICH Q5A R2 Guideline
   - Regulatory Requirements for Virus Safety Testing and Virus Clearance Studies
   - Impact of Regulatory Requirements on Business

2. CURRENT AND EMERGING VIRUSES
   - Hepatitis E Virus
   - Paroviruses
   - COVID-19
   - Zika
   - West Nile
   - Swine flu
   - Measles
   - MERS
   - Ebola
   - Monkey Pox
   - Circovirus
   - Zoonoses

3. VIRUS SAFETY OF STARTING AND RAW MATERIALS
   - Risk Assessment
   - Virus Mock Particles
   - Case Studies for Media Treatment
   - New Threats to Human Plasma
   - Cell Substrate Safety
   - Raw Materials
   - Material Selection
   - Supplier Audits and Qualification
   - Cell-Sorting Antibodies
   - Serum and Trypsin
   - Antibody Drug Conjugates
   - Adventitious Viruses/Adventitious Agents
   - Prevention of Contamination
   - Utilization of Prior Knowledge
   - Substances of Human Origin and Animal-Derived

4. VIRUS DETECTION AND IDENTIFICATION
   - Virus Detection Methods
   - Virus-Like Particles
   - Developments of New Detection Methods
   - Next Generation Sequencing/High Throughput Sequencing
   - Technical Operation of Next Generation Sequencing Platforms, e.g., Automation, Time to Result
   - Targeted vs. Agnostic Next Generation Sequencing
   - Next Generation Sequencing Bioinformatics
   - Product-Enhanced Reverse Transcriptase Assay
   - Nucleic Acid-Based Methods
   - Digital-Droplet Polymerase Chain Reaction
   - Model Organisms, Equipment, and Conditions
   - Replacement of Animal/In-Vivo Tests and 3R Initiative
   - Cell-Based Assays/HEV Infectivity Assay
   - Emerging and Hard-to-Detect Viruses
   - Transmission Electron Microscopy
   - Artificial Intelligence

CASE STUDIES AND CURRENT CHALLENGES ARE OF SPECIAL INTEREST.

data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAYAAAAAgCAYAAABlamYcAAAAGXRFWHRTb2Z0d2FyZQBBZG9iZSBJbWFnZVJlYWR5ccllPAAAAyJpVFh0WE1MOmNvbS5hZG9iZS54bXAAAAAAADw/eHBhY2tldCBiZWdpbj0i77u/IiBpZD0iVzVNME1wQ2VoaUh6cmVTek5UY3prYzlkIj8+4w EE3SkS/6H7/i4+6mgADEmE/DKVi/6GwCaVObKu7/+GwwBFTAgY5JIlx+7gwzzhgAEDKgiMvRJBGDwZwFJawk/yzzEAAAAAElFTkSuQmCC
5. VIRAL SAFETY OF ATMPS
- Human Platelet Lysates and Sera
- Viral Vectors
- Virus Safety of Cell Lines
- Helper Virus Production
- Viral Clearance
- Viral Vector Purification Process
- Xenogenic Cells Used as Feeder Layer or Therapeutic Substance
- Case Studies for Cell and Gene-Based Medicinal Products
- Extracellular Vesicles
- Virus Reduction Studies
- Transplantation (e.g., Xenotransplantation)
- Medical Devices

6. VIRAL CONTAMINATION AND RISK MITIGATION
- Raw Materials
- Blood Products
- Cell-Based Products
- Cell Substrates
- Infectability of Cell Substrates
- New Concepts for Testing and Identification
- Inactivation Strategies and Equipment

7. TSE CONTAMINATION AND RISK MITIGATION
- Raw Materials
- Blood Products
- Cell-Based Products
- Cell Substrates
- Infectability of Cell Substrates
- New Concepts for Testing and Identification
- Inactivation Strategies and Equipment

8. ASPECTS OF FOOD AND WATERBORNE VIRUS SAFETY
- Norovirus-Related Diseases
- Rotavirus-Related Diseases
- Identification of Viruses in Food Matrixes
- Transmission Pathways
- Risk Assessments
- Cultured Meat Products

9. VIRUS SAFETY IN MANUFACTURING
- Biopharmaceuticals
- Plasma-Derived Medicinal Products
- Viral Vaccines
- Irradiation (Gamma, Electrons, X-Rays)
- Inactivation
- Removal
- Filtration
- Prion-Specific Filtration Methods
- Chromatography
- Precipitation
- Case Studies
- Risk Assessments
- Continuous Manufacturing
- Platform Approach
- Technical Developments/Innovation
- Analytical Methods
- Integrated Recycling Process
- Reduction of Wastewater
- Waste Prevention and Handling
- Environmental Protection
- Recycling Economy

10. VIRUS REDUCTION STUDIES
- Design of Studies
- DoE Studies
- Case Studies on Platform Validation
- Mechanism of Action of Virus Removal/Inactivation
- Robustness of Specific Unit Operations
- Identification of Critical Process Parameters
- Spike Preparations
- Scalability of Study Design and Study Results
- Sanitization of Chromatographic Equipment
- Columns Including Virus-Carry-Over Studies
- Impact of Virus Spike Quality
- Developments in Laboratory Automation

VENUE
AMSTERDAM MARRIOTT HOTEL
Stadhouderskade 12, 1054 ES Amsterdam, The Netherlands
Tel: +31 20-6075555
E-Mail: Amsterdam@Marriott.com | https://bit.ly/461euWo

INFORMATION
SCIENTIFIC PROGRAM PLANNING COMMITTEE
Andy Bailey, ViruSure
Sean O’Donnell, Eli Lilly and Company
Alison Armstrong, Merck KGaA
Chakameh Azimpour, Amgen
Johannes Bluemel, Paul-Ehrlich-Institut
David Cetlin, Cygnus
Qi Chen, Genentech/Roche
Tomoko Hongo, Asahi Kasei
Arifa Khan, U.S. FDA
Thomas R. Kreil, Takeda
Remo Leisi, CSL Behring
Sebastian Teitz, Biopharma Excellence
Josh Eaton, PDA
Falk Klar, PDA Europe
Stefanie Nebelin, Senior Manager Programs & Events, PDA Europe
SUBMISSION PROCESS

DEADLINE: 30 NOVEMBER 2023

All submitted abstracts will be reviewed by the Scientific Program Planning Committee for acceptance. PDA Europe will provide a complimentary registration per on-site podium presentation.

Additional on-site presenters are required to pay the conference registration fee.

Abstracts not selected for a podium presentation may be invited to join as a scientific poster contribution. On-site poster presenters are required to pay the conference registration fee and an additional printing fee will apply.

THE ONLINE PROCESS ASKS YOU TO PROVIDE THE FOLLOWING INFORMATION:

- PRESENTATION TITLE
- PRESENTER’S NAME AND CONTACT DETAILS
- PRESENTER’S BIOGRAPHY (APPROX. 100 WORDS)
- ADDITIONAL SPEAKERS (IF APPLICABLE)
- KEY OBJECTIVES OF TOPIC
- 2-3 PARAGRAPH ABSTRACT, SUMMARIZING THE TOPIC (MAX 300 WORDS)

Please click or scan the QR Code to submit your abstract.

If you have any further questions, please do not hesitate to contact programs-europe@pda.org

TO EXHIBIT: PDA is seeking vendors who provide products/services in support of this conference. Space on-site is limited and is on a first-come, first-serve basis. To reserve your space, please contact Christopher Haertig at expo-europe@pda.org.
SCIENTIFIC POSTER PRESENTATION

ALL POSTERS WILL BE PRINTED BY PDA AND DISPLAYED AS PART OF THE EXHIBITION.
Please send your file and poster title to Christopher Haertig expo-europe@pda.org.

JOIN OUR GUIDED POSTER WALK IN OUR EXHIBITION HALL AND GAIN MORE VISIBILITY
YOU WILL HAVE THE CHANCE TO ENGAGE WITH OUR POSTER AUDIENCE!

DEADLINE: 10 MAY 2024

Canvas Size to Work on:
85 cm x 120 cm (33,465 x 47,244 in)
Portrait Format
Slug / Bleed: 2 mm (0,079 in)

Images:
120 dpi (low) - 150 dpi (high)
Depending on size.
All Images Color Profile
ISO Coated v2 (ECI)

Document size of the PDF:
85 cm x 206 cm (33,465 x 81,102 in)
Portrait Format
Slug / Bleed: 2 mm (0,079 in)

To join our scientific poster session, the poster has to be non-commercial in nature.
Please send a printable PDF file according to the following specifications:
<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09-10 APR 2024</td>
<td>2024 PDA Visual Inspection Forum</td>
<td>Munich, Germany</td>
</tr>
<tr>
<td>23-24 APR 2024</td>
<td>2024 PDA Parenteral Packaging Conference</td>
<td>Copenhagen, Denmark</td>
</tr>
<tr>
<td>15-16 MAY 2024</td>
<td>2024 PDA Good Aseptic Manufacturing Conference</td>
<td>Stuttgart, Germany</td>
</tr>
<tr>
<td>04-05 JUN 2024</td>
<td>2024 PDA Good Digitalization in Pharma Conference</td>
<td>TBA</td>
</tr>
<tr>
<td>04-05 JUN 2024</td>
<td>2024 PDA Medical Devices and Connected Health Conference</td>
<td>TBA</td>
</tr>
<tr>
<td>06 JUN 2024</td>
<td>2024 PDA Artificial Intelligence in Pharma Workshop</td>
<td>TBA</td>
</tr>
<tr>
<td>06 JUN 2024</td>
<td>2024 PDA The Future of Drug Delivery Workshop</td>
<td>TBA</td>
</tr>
<tr>
<td>24-25 JUN 2024</td>
<td>2024 PDA Advanced Therapy Medicinal Products Conference</td>
<td>Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>26-27 JUN 2024</td>
<td>2024 PDA Virus Conference</td>
<td>Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>28 JUN 2024</td>
<td>2024 PDA Next-Generation Sequencing Workshop</td>
<td>Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>24-25 SEP 2024</td>
<td>2024 PDA BioManufacturing Conference</td>
<td>Gothenburg, Sweden</td>
</tr>
<tr>
<td>26 SEP 2024</td>
<td>2024 PDA Sustainability in Pharma Workshop</td>
<td>Gothenburg, Sweden</td>
</tr>
</tbody>
</table>